We are live on ! Find out more
FOMX

Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX

Delisted

FOMX was delisted on the 6th of March, 2020.

77 hedge funds and large institutions have $127M invested in Foamix Pharmaceuticals Ltd. Ordinary Shares in 2015 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 41 increasing their positions, 14 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

193% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 14

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

8% less funds holding

Funds holding: 8477 (-7)

23% less capital invested

Capital invested by funds: $164M → $127M (-$37.3M)

50% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 14

Holders
77
Holders Change
-7
Holders Change %
-8.33%
% of All Funds
2.15%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
7
Increased
41
Reduced
14
Closed
14
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$15M
Franklin Resources
2
Franklin Resources
California
$12.4M +$1.32M +129,400 +8%
MMH
3
Menora Mivtachim Holdings
Israel
$9.9M +$2.22M +217,457 +19%
DA
4
DSC Advisors
Illinois
$7.33M +$156K +15,266 +2%
DM
5
Deerfield Management
New York
$6.96M
SAM
6
Senzar Asset Management
New York
$6.34M +$1.6M +156,959 +22%
Bank of New York Mellon
7
Bank of New York Mellon
New York
$5.65M +$1.17M +114,680 +17%
TCM
8
Tekla Capital Management
Massachusetts
$4.5M +$2.04M +199,777 +48%
BFA
9
BlackRock Fund Advisors
California
$4.38M +$42K +4,120 +0.7%
DCM
10
Driehaus Capital Management
Illinois
$4.02M +$1.74M +171,108 +45%
Alyeska Investment Group
11
Alyeska Investment Group
Illinois
$3.74M +$398K +39,093 +8%
PHS
12
PFM Health Sciences
California
$3.72M +$612K +60,011 +13%
JGC
13
J. Goldman & Co
New York
$3.48M +$711K +69,810 +17%
SFM
14
Sphera Funds Management
Israel
$2.79M
UBS AM
15
UBS AM
Illinois
$2.51M +$576K +56,558 +20%
SCM
16
Sio Capital Management
New York
$2.46M +$1.78M +175,000 +109%
AC
17
Ascend Capital
California
$2.2M +$1.47M +144,000 +92%
OM
18
Opaleye Management
Massachusetts
$2.09M +$2.04M +200,000 +235%
Acadian Asset Management
19
Acadian Asset Management
Massachusetts
$2.08M -$787K -77,196 -21%
CCM
20
Cadian Capital Management
New York
$1.96M +$2.72M +267,236 New
SM
21
Sabby Management
Florida
$1.78M +$687K +67,361 +38%
State Street
22
State Street
Massachusetts
$1.76M +$626K +61,388 +34%
Baillie Gifford & Co
23
Baillie Gifford & Co
United Kingdom
$1.61M +$306K +30,000 +16%
EI
24
EAM Investors
California
$1.6M -$438K -42,961 -16%
Northern Trust
25
Northern Trust
Illinois
$1.45M +$1.83M +179,457 +969%

FOMX Hedge Fund Activity: Q3 2015 in Review

77 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) for Q3 2015, worth a combined $127M — down 23% from $164M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of FOMX and 7 opened new positions — a net loss of 7 holders — while 14 trimmed existing stakes and 41 added.

The largest buyer was Cadian Capital Management, opening a new position worth an estimated $2.72M. The largest seller was Visium Asset Management, exiting entirely with an estimated $7.93M sold.

  • 77 institutional investors held Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) as of Q3 2015, down from 84 in Q2 2015.
  • Funds reported $127M of Foamix Pharmaceuticals Ltd. Ordinary Shares stock for Q3 2015, down 23% quarter-over-quarter.
  • 7 funds opened new Foamix Pharmaceuticals Ltd. Ordinary Shares positions in Q3 2015 and 14 closed out, a net change of -7 holders.
  • The largest Foamix Pharmaceuticals Ltd. Ordinary Shares buyer in Q3 2015 was Cadian Capital Management, an estimated $2.72M added.
  • The largest Foamix Pharmaceuticals Ltd. Ordinary Shares seller in Q3 2015 was Visium Asset Management, an estimated $7.93M sold.

Based on aggregated 13F filings for Q3 2015.